Login to Your Account

Pretty tough challenge: PTC taps resilience to weather the Translarna storm

By Michael Fitzhugh
Staff Writer

Tuesday, March 1, 2016

Shares of PTC Therapeutics Inc.  hit a record low of $5.29 on Tuesday after the company further detailed the FDA's refusal to accept a new drug application (NDA) for its Duchenne muscular dystrophy candidate, Translarna.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription